Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
NEO Stock Forecast 2026-2027
$7.98
Current Price
$1.04B
Market Cap
Buy 6
Hold 7
Sell 0
Wall St Analyst Ratings
Distance to NEO Price Targets
+113.0%
To High Target of $17.00
+88.0%
To Median Target of $15.00
+62.9%
To Low Target of $13.00
NEO Price Momentum
-10.9%
1 Week Change
-29.9%
1 Month Change
-18.7%
1 Year Change
-32.1%
Year-to-Date Change
-41.9%
From 52W High of $13.74
+69.1%
From 52W Low of $4.72
📊 TOP ANALYST CALLS
Did NEO Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if NeoGenomics is one of their latest high-conviction picks.
Latest NEO Stock Price Targets & Analyst Predictions
Based on our analysis of 16 Wall Street analysts, NEO has a neutral consensus with a median price target of $15.00 (ranging from $13.00 to $17.00). The overall analyst rating is Buy (7.5/10). Currently trading at $7.98, the median forecast implies a 88.0% upside. This outlook is supported by 6 Buy, 7 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Tejas Savant at Morgan Stanley, projecting a 113.0% upside. Conversely, the most conservative target is provided by David Westenberg at Piper Sandler, suggesting a 62.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
NEO Analyst Ratings
6
Buy
7
Hold
0
Sell
NEO Price Target Range
Low
$13.00
Average
$15.00
High
$17.00
Current: $7.98
Latest NEO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for NEO.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 24, 2026 | Piper Sandler | David Westenberg | Overweight | Maintains | $13.00 |
| Feb 17, 2026 | Needham | Mike Matson | Buy | Maintains | $15.00 |
| Jan 12, 2026 | Needham | Mike Matson | Buy | Reiterates | $14.00 |
| Sep 12, 2025 | TD Cowen | Dan Brennan | Buy | Maintains | $12.00 |
| Sep 2, 2025 | Stephens & Co. | Mason Carrico | Overweight | Maintains | $11.00 |
| Aug 29, 2025 | Needham | Mike Matson | Buy | Maintains | $14.00 |
| Aug 4, 2025 | Piper Sandler | David Westenberg | Overweight | Maintains | $11.00 |
| Jul 30, 2025 | Morgan Stanley | Tejas Savant | Equal-Weight | Maintains | $8.00 |
| Jul 29, 2025 | William Blair | Market Perform | Downgrade | $N/A | |
| Jul 29, 2025 | Needham | Mike Matson | Buy | Maintains | $8.00 |
| May 6, 2025 | Piper Sandler | David Westenberg | Overweight | Maintains | $12.00 |
| May 1, 2025 | Morgan Stanley | Tejas Savant | Equal-Weight | Maintains | $10.00 |
| Apr 30, 2025 | Goldman Sachs | Matthew Sykes | Buy | Maintains | $10.00 |
| Apr 30, 2025 | Leerink Partners | Puneet Souda | Market Perform | Downgrade | $9.00 |
| Apr 29, 2025 | Needham | Mike Matson | Buy | Maintains | $8.50 |
| Apr 17, 2025 | Goldman Sachs | Matthew Sykes | Buy | Maintains | $15.00 |
| Feb 26, 2025 | Piper Sandler | David Westenberg | Overweight | Maintains | $18.00 |
| Feb 19, 2025 | Needham | Mike Matson | Buy | Maintains | $18.00 |
| Feb 19, 2025 | B of A Securities | Derik De Bruin | Neutral | Maintains | $16.00 |
| Jan 28, 2025 | Goldman Sachs | Matthew Sykes | Buy | Maintains | $18.00 |
NeoGenomics Inc. (NEO) Competitors
The following stocks are similar to NeoGenomics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
NeoGenomics Inc. (NEO) Financial Data
NeoGenomics Inc. has a market capitalization of $1.04B with a P/E ratio of -9.6x. The company generates $727.33M in trailing twelve-month revenue with a -14.9% profit margin.
Revenue growth is +10.6% quarter-over-quarter, while maintaining an operating margin of -6.6% and return on equity of -12.4%.
Valuation Metrics
Market Cap
$1.04B
Enterprise Value
$1.29B
P/E Ratio
-9.6x
PEG Ratio
0.3x
Price/Sales
1.4x
Growth & Margins
Revenue Growth (YoY)
+10.6%
Gross Margin
+43.8%
Operating Margin
-6.6%
Net Margin
-14.9%
EPS Growth
+10.6%
Financial Health
Cash/Price Ratio
+15.4%
Current Ratio
4.3x
Debt/Equity
48.9x
ROE
-12.4%
ROA
-2.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
NeoGenomics Inc. (NEO) Business Model
About NeoGenomics Inc.
What They Do
Provides comprehensive cancer diagnostics and testing services.
Business Model
The company generates revenue by offering a wide range of oncology genetics testing services, including next-generation sequencing and genomic profiling. It serves various clients, including pathologists, oncologists, and pharmaceutical companies, through clinical testing, research services, and specialized assay offerings.
Additional Information
Founded in 1998 and headquartered in Fort Myers, Florida, NeoGenomics operates CAP-accredited and CLIA-certified laboratories in the U.S. and the UK. The company's Pharma Services Division also supports drug development, positioning it as a crucial player in the field of precision oncology.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
2,200
CEO
Mr. Anthony P. Zook
Country
United States
IPO Year
2004
Website
www.neogenomics.comNeoGenomics Inc. (NEO) Latest News & Analysis
Latest News
Quick Summary
NeoGenomics has launched RaDaR® ST, a circulating tumor DNA assay designed to detect molecular residual disease.
Why It Matters
NeoGenomics' launch of RaDaR® ST enhances its product portfolio in cancer diagnostics, potentially increasing revenue and market share, which can positively impact stock performance.
Source: Business Wire
Market Sentiment:
Neutral
After Plunging 22.8% in 4 Weeks, Here's Why the Trend Might Reverse for NeoGenomics (NEO)
21 days ago
Quick Summary
NeoGenomics (NEO) is currently oversold, suggesting reduced selling pressure. Analysts are also revising earnings estimates upward, indicating a possible trend reversal.
Why It Matters
NeoGenomics being oversold suggests a potential rebound, and analysts' upgraded earnings estimates may signal improved performance, creating a favorable outlook for investors.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
NeoGenomics will attend the TD Cowen 46th Annual Health Care Conference in Boston and the Leerink Global Healthcare Conference in Miami.
Why It Matters
NeoGenomics' participation in major healthcare conferences signals potential visibility and investment interest, which could impact its stock performance and investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
NeoGenomics, Inc. (NEO) held its Q4 2025 earnings call, discussing financial performance and key business updates. Further details on revenue and growth strategies were shared.
Why It Matters
NeoGenomics' Q4 2025 earnings call provides insights into financial performance, growth trends, and strategic direction, impacting investor confidence and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
NeoGenomics released its fourth-quarter and full-year financial results for the period ending December 31, 2025.
Why It Matters
NeoGenomics' quarterly and annual results can impact stock performance, providing insights into financial health, growth potential, and market position, influencing investor sentiment and decisions.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
NeoGenomics (NEO) reported quarterly earnings of $0.06 per share, exceeding the Zacks Consensus Estimate of $0.04 and up from $0.04 per share a year earlier.
Why It Matters
NeoGenomics' earnings beat estimates, indicating better-than-expected performance and growth year-over-year, which can boost investor confidence and potentially drive stock prices higher.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About NEO Stock
What is NeoGenomics Inc.'s (NEO) stock forecast for 2026?
Based on our analysis of 16 Wall Street analysts, NeoGenomics Inc. (NEO) has a median price target of $15.00. The highest price target is $17.00 and the lowest is $13.00.
Is NEO stock a good investment in 2026?
According to current analyst ratings, NEO has 6 Buy ratings, 7 Hold ratings, and 0 Sell ratings. The stock is currently trading at $7.98. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for NEO stock?
Wall Street analysts predict NEO stock could reach $15.00 in the next 12 months. This represents a 88.0% increase from the current price of $7.98. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is NeoGenomics Inc.'s business model?
The company generates revenue by offering a wide range of oncology genetics testing services, including next-generation sequencing and genomic profiling. It serves various clients, including pathologists, oncologists, and pharmaceutical companies, through clinical testing, research services, and specialized assay offerings.
What is the highest forecasted price for NEO NeoGenomics Inc.?
The highest price target for NEO is $17.00 from Tejas Savant at Morgan Stanley, which represents a 113.0% increase from the current price of $7.98.
What is the lowest forecasted price for NEO NeoGenomics Inc.?
The lowest price target for NEO is $13.00 from David Westenberg at Piper Sandler, which represents a 62.9% increase from the current price of $7.98.
What is the overall NEO consensus from analysts for NeoGenomics Inc.?
The overall analyst consensus for NEO is neutral. Out of 16 Wall Street analysts, 6 rate it as Buy, 7 as Hold, and 0 as Sell, with a median price target of $15.00.
How accurate are NEO stock price projections?
Stock price projections, including those for NeoGenomics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: March 13, 2026 2:18 PM UTC